Skip to main content
. Author manuscript; available in PMC: 2010 Mar 22.
Published in final edited form as: Toxicol Pathol. 2009;37(7):969–982. doi: 10.1177/0192623309350475

Figure 5.

Figure 5

Representative Western blots and bar graphs illustrate renal angiotensin-II receptor expression. (A) Lower renal angiotensin II type 2 receptor (AT2R) expression in ovx compared to intact aldosterone-salt–treated (AST) rats was restored by estrogen treatment. Medroxyprogesterone acetate (MPA) blocked the increase of AT2R expression in estradiol-treated rats. Drospirenone and SPIRO further enhanced renal AT2R expression in estradiol-treated animals. (B) Renal AT1R expression was comparable among all animals (n = 10 animals/group; *p < .05 vs. ovx AST placebo and ovx AST + E2 + MPA). (C) Antibody competition assay illustrating the specificity of the AT2R antibody for its cognate polypeptide. Renal extracts (100 μg/lane) from six independent animals were subjected to Western blotting and probing with the polyclonal anti-AT2R antibody after pre-incubation with a specific blocking peptide or buffer. Note the disappearance of the 30 KD band representing the rat renal AT2R upon pre-incubation of the AT2R antibody with the blocking peptide.